Glycosylation-Independent Alpha-Galactosidase A for Fabry Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for Fabry disease are limited by high doses required, frequent infusions, and significant side effects, including immune responses, due to the inability of alpha-galactosidase A to cross the blood-brain barrier and maintain biological activity.
Innovation Solution
Engineered alpha-galactosidase A polypeptides with non-glycosylation mutations and compensatory mutations that allow for targeted delivery and increased resistance to proteases, enabling lower doses and reduced frequency of infusions while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of alpha-galactosidase A are administered, then therapeutic efficacy is improved, but immune responses and side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the molecular structure of alpha-galactosidase A through specific amino acid substitutions (e.g., N215Q, N192Q, N139Q mutations) that eliminate glycosylation sites. This structural parameter change reduces immunogenicity while maintaining or improving enzymatic activity, allowing effective treatment at lower doses with reduced immune responses
2Reliability
If frequent infusions are administered, then therapeutic efficacy is maintained, but treatment complexity and patient burden increase
Solution Approach 1:
The patent employs partial action by introducing specific mutations (such as E203C, Y207W, M208E, F211X) that partially modify the enzyme structure to enhance its properties. These partial modifications result in improved stability, protease resistance, and half-life, allowing less frequent infusions while maintaining therapeutic efficacy
3Adaptability or versatility
If alpha-galactosidase A is used for systemic treatment, then broad disease coverage is achieved, but blood-brain barrier penetration is insufficient
Solution Approach 1:
The patent applies local quality by making site-specific modifications to the enzyme structure through targeted amino acid substitutions. These localized changes at specific positions (e.g., mutations in the 198-217 region) confer enhanced properties including improved blood-brain barrier penetration capability while maintaining the enzyme's overall therapeutic function for systemic disease coverage
4Object-affected harmful factors
If lower enzyme doses are administered, then immune responses are reduced, but therapeutic efficacy may be compromised
Solution Approach 1:
The patent resolves this contradiction through parameter changes that increase the specific activity and stability of the engineered enzyme. By modifying amino acid sequences to eliminate glycosylation sites and introduce stabilizing mutations, the enzyme achieves higher potency per unit dose, maintaining therapeutic efficacy at lower doses with reduced immunogenicity
Data Source
AI summary
A engineered alpha-galactosidase A polypeptide comprising SEQ ID NO: 1 having at least one non-glycosylation mutation; and at least one glycosylation compensatory mutation is claimed.